Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018
Military Medicine · 2023
DOI: 10.1093/milmed/usac428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Military Medicine, 2023. Verfasst von Zachary C Junga und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
The objective of this study was to measure the number of treatment successes and failures of various Helicobacter pylori treatment regimens among DoD beneficiaries. Materials and Methods This was a retrospective cross-sectional study of all adult DoD beneficiaries with H. pylori diagnosis, treatment, and eradication testing from October 2015 to September 2018. All stool antigen testing, urea breath test, and immunoglobulin G serologies were identified. Patients were excluded if they did not have a positive test, did not have treatment, or did not have eradication testing.
Results
In total, 20,548 H. pylori diagnostic tests were performed over the study period. A total of 1,592 non–active duty and 374 active duty patients were diagnosed with H. pylori, were treated, and had eradication testing. The best performing regimens were tetracycline-based bismuth quadruple therapy and tinidazole-based clarithromycin triple therapy with eradication rates of 85% and 82%, respectively. Clarithromycin triple therapy was the most prescribed (63.9% of all regimens included in analysis). Of the 1,592 non–active duty and 374 active duty patients, 75.5% (1,202) and 70.6% (264) cleared the infection with treatment, respectively (P = 0.0449). Although trends were identified in differences in geographic eradication rates, none of these achieved the threshold of significance.
Conclusions
This is the largest and most geographically widespread H. pylori treatment efficacy study in the USA over 20 years. None of the treatment regimens (when used in over five patients) achieved an eradication rate greater than 90%, but tetracycline-based bismuth quadruple therapy performed best among all regimens and populations. Eradication rates were lower in the active duty populations, with no treatment regimen achieving an eradication rate greater than 80%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA.
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20889, USA.
- Gastroenterology Service, Landstuhl Regional Medical Center, Landstuhl 66849, Germany.
- Department of Medicine, Division of Gastroenterology, Naval Medical Center San Diego, San Diego, CA 92134, USA.
Zitieren
APA
Junga, Z. C., Mertz, A., Pak, K., & Singla, M. (2023). Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018. Military Medicine. https://doi.org/10.1093/milmed/usac428
Vancouver
Junga ZC, Mertz A, Pak K, Singla M. Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018. Military Medicine. 2023. doi:10.1093/milmed/usac428
BibTeX
@article{Junga2023,
author = {Junga, Zachary C and Mertz, Andrew and Pak, Kevin and Singla, Manish},
title = {Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018},
journal = {Military Medicine},
year = {2023},
doi = {10.1093/milmed/usac428}
}
EUVIMED